What does the drug do?
Changes in metabolism and the way energy is used in the body has been seen in MND. In many cases, these changes cause the body to expend more energy than a normal and have been linked to faster disease progression. Trimetazidine is a partial fatty acid oxidation inhibitor and repurposed treatment which is used to correct metabolic disturbances in angina. In MND, the drug shows promise in slowing disease progression by reducing heightened metabolism and oxidative stress.
Phase 2 - MetFlex
The Phase 2a investigator led, open-label, single-arm trial will evaluate the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). The trial will aim to recruit 36 participants across centres. You can find out more about the trial here.
The trial is currently not yet recruiting in the UK at the following sites:
- London (King's College London)
2021 - The trial opened for enrollment in Australia and the Netherlands.
Last updated: 01/08/2022